Anbio Biotechnology 6-K, filed Dec 30, 2025
Anbio Biotechnology (NNNN)
About this 6-K
Anbio Biotechnology filed this 6-K on December 30, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2025
Commission File Number: 001-42526
Anbio Biotechnology
Friedrich-Ebert-Anlage 35-37, 60327
Frankfurt am Main,
Germany
+49 69870039170
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On December 30, 2025, Anbio Biotechnology, a Cayman Islands exempted company issued a press release entitled “Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025.” A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release - Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Anbio Biotechnology | ||
| Date: December 30, 2025 | By: | /s/ Michael Lau |
| Name: | Michael Lau | |
| Title: | Chief Executive Officer | |
2
Exhibit 99.1
Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025
Germany, December 30, 2025 - Anbio Biotechnology (Nasdaq: NNNN, the “Company” or “Anbio”), a medical device company focused on in vitro diagnostic (“IVD”) solutions, today announced its unaudited condensed consolidated financial results which have not been reviewed by an independent certified public accountant for the six months ended June 30, 2025.
Financial Highlights for the Six Months Ended June 30, 2025
| ● | Revenue was approximately $4.58 million, compared to $5.85 million for the same period in 2024. |
| ● | Net income was approximately $3.80 million, compared to $3.60 million for the six months ended June 30, 2024. |
Financial Results
Revenues
For the six months ended June 30, 2025, the Company generated total revenue of approximately $4.6 million, compared to approximately $5.8 million for the same period in 2024. The decrease in revenue was primarily attributable to changes in product mix and the Company’s strategy to selectively accept orders based on gross margin and overall profitability considerations.
Gross Profit
Gross profit for the six months ended June 30, 2025 was approximately $4.2 million, representing a gross margin of approximately 92.3%, compared to approximately $3.9 million, or a gross margin of approximately 66.9%, for the same period in 2024. The increase in gross margin was primarily due to higher-margin products launched in 2025 and effective procurement cost controls.
Income from Operations
Operating income for the six months ended June 30, 2025 was approximately $3.4 million, compared to approximately $3.6 million for the same period in 2024.
Net Income
Net income for the six months ended June 30, 2025 was approximately $3.8 million, compared to approximately $3.6 million in the prior-year period.
Operating Expenses
Selling, general and administrative expenses increased during the period primarily due to higher professional fees associated with the Company’s public listing and related regulatory compliance activities. Research and development expenses remained relatively consistent year over year, reflecting continued investment in new diagnostic products and assay development.
Liquidity and Capital Resources
As of June 30, 2025, the Company had cash and cash equivalents of approximately $5.3 million and working capital of approximately $27.5 million. The Company believes that its current cash position, together with proceeds from its initial public offering completed in February 2025 and cash generated from operations, will be sufficient to meet its anticipated operating and capital requirements for at least the next twelve months.
Business Update
During the six months ended June 30, 2025, approximately 94.6% of the Company’s commercial IVD revenue was generated from non-COVID products, reflecting the Company’s continued transition toward a diversified portfolio of diagnostic solutions beyond COVID-related testing.
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of IVD products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and six key platforms for biomarker detection. These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a strong global presence across the EU, APAC, and the Americas, the Company’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are not guarantee of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict and many of which are beyond the control of Anbio. Actual results may differ from those projected in the forward-looking statements due to risks and uncertainties, as well as other risk factors that are included in the Company’s filings with the U.S. Securities and Exchange Commission. Although Anbio believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by Anbio or any other person that their objectives or plans will be achieved. Anbio does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
2
ANBIO BIOTECHNOLOGY
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in U.S. Dollars, except for the number of shares)
June 30, (Unaudited) | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,348,490 | $ | 11,760,859 | ||||
| Accounts receivable, net | 3,716,379 | 1,064,794 | ||||||
| Short-term investment | 8,080,502 | — | ||||||
| Prepayment | 10,173,063 | 5,683,085 | ||||||
| Prepaid and other current assets | 362,160 | 25,606 | ||||||
| Total Current Assets | 27,680,594 | 18,534,344 | ||||||
| Deferred offering cost | — | 387,440 | ||||||
| TOTAL ASSETS | $ | 27,680,594 | $ | 18,921,784 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 60,350 | $ | 1,625,255 | ||||
| Other current liabilities | 70,777 | 104,979 | ||||||
| Total Current Liabilities | 131,127 | 1,730,234 | ||||||
| TOTAL LIABILITIES | 131,127 | 1,730,234 | ||||||
| Shareholders’ Equity: | ||||||||
| Class A ordinary shares, $0.0001 par value, 400,000,000 shares authorized, 43,891,200 and 42,291,200 issued and outstanding at June 30, 2025 and December 31, 2024 | 4,389 | 4,229 | ||||||
| Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized, 100,000,000 issued and outstanding at June 30, 2025 and December 31, 2024 | 10,000 | 10,000 | ||||||
| Additional paid-in capital | 6,563,630 | 3,780 | ||||||
| Retained earnings | 20,971,448 | 17,173,541 | ||||||
| Total Shareholders’ Equity | 27,549,467 | 17,191,550 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 27,680,594 | $ | 18,921,784 | ||||
3
ANBIO BIOTECHNOLOGY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenues | $ | 4,584,640 | $ | 5,849,633 | ||||
| Total Revenues | 4,584,640 | 5,849,633 | ||||||
| Cost of Revenues | 351,939 | 1,939,013 | ||||||
| Gross Profit | 4,232,701 | 3,910,620 | ||||||
| Operating Expenses | ||||||||
| Selling, general and administrative | 734,125 | 184,554 | ||||||
| Research and development | 131,305 | 127,700 | ||||||
| Total operating expenses | 865,430 | 312,254 | ||||||
| Income from operations | 3,367,271 | 3,598,366 | ||||||
| Other Income (Expenses) | ||||||||
| Interest and investment income | 140,237 | 138,464 | ||||||
| Unrealized investment loss | (164,354 | ) | — | |||||
| Foreign exchange gain (loss) | 454,615 | (140,186 | ) | |||||
| Others, net | 138 | — | ||||||
| Total other (expenses) income | 430,636 | (1,722 | ) | |||||
| Income before provision for income taxes | 3,797,907 | 3,596,644 | ||||||
| Provision for income taxes | — | — | ||||||
| Net income | $ | 3,797,907 | $ | 3,596,644 | ||||
| Basic and diluted earnings per Class A share | $ | 0.087 | $ | 0.085 | ||||
| Weighted average shares outstanding-Class A | 43,449,213 | 42,291,200 | ||||||
4